Dabrafenib/Trametinib Combo Provides Lasting Control for BRAF V600-Mutant Metastatic Melanoma
Source: OncLive, July 2019
Five years out, one-third of patients with unresectable or metastatic BRAF V600-mutant melanoma remained alive following treatment with dual targeted therapy with dabrafenib (Tafinlar) plus trametinib (Mekinist), and 1 in 5 remained alive without progression, according to an analysis COMBI-d and COMBI-v trials reported at the 2019 ASCO Annual Meeting.1
Pooled data from 2 randomized trials of the BRAF inhibitor and MEK-targeted trametinib (Mekinist) showed a 5-year overall survival (OS) of 34% among 563 evaluable patients. Additionally, 19% of the patients were living without disease progression at 5 years.
Patients who achieved complete responses had the best odds of attaining long-term benefit, said Paul Nathan, MBBS, PhD, FRCP, in the Department of Medical Oncology, Mount Vernon Cancer Centre.